As half of the advanced melanoma patients bear mutations at the residue Val 600 in the kinase BRAF that lead to constitutive activation of the MAPK pathway [6], targeted therapies including BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib) have been developed [[7], [8], [9], [10], [11]]. Here, BRAF is linked to melanoma.